InMed Pharmaceuticals amends merger pact with Mentari Therapeutics
InMed Pharmaceuticals announced that it has entered into an amendment to the previously announced definitive merger agreement for an all-stock transaction with Mentari Therapeutics, a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp., a wholly-owned subsidiary of